Prognostic factors in rheumatoid arthritis in the era of biologic agents. (Q37563990)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19636334%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

review article

1 reference

title

Prognostic factors in rheumatoid arthritis in the era of biologic agents (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19636334%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19636334%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Hendrik Schulze-Koops

series ordinal

3

object named as

Hendrik Schulze-Koops

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19636334%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

1

Alla Skapenko

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19636334%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

language of work or name

English

0 references

publication date

28 July 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19636334%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Rheumatology

3 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19636334%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

volume

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19636334%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19636334%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

page(s)

491-496

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19636334%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nrrheum.2009.157

3 February 2020

exact match

0 references

cites work

Prognostic factors in early rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.157

A simple algorithm to predict the development of radiological erosions in patients with early rheumatoid arthritis: prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.157

EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.157

American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.157

Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.157

The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.157

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.157

Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.157

Association of the TRAF1/C5 locus with increased mortality, particularly from malignancy or sepsis, in patients with rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.157

Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.157

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.157

Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.157

What is the natural history of rheumatoid arthritis?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.157

Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.157

Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.157

Prognostic markers of radiographic progression in early rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.157

How to diagnose rheumatoid arthritis early: A prediction model for persistent (erosive) arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.157

Clinical identification and treatment of a rapidly progressing disease state in patients with rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.157

Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.157

Incidence and predictors of severe extra-articular disease manifestations in an early rheumatoid arthritis inception cohort

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.157

Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.157

Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.157

Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.157

Magnetic resonance imaging findings in 84 patients with early rheumatoid arthritis: bone marrow oedema predicts erosive progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.157

Bone oedema predicts erosive progression on wrist MRI in early RA--a 2-yr observational MRI and NC scintigraphy study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.157

Longitudinal power Doppler ultrasonographic assessment of joint inflammatory activity in early rheumatoid arthritis: predictive value in disease activity and radiologic progression.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.157

Hypervascular synovitis and American College of Rheumatology Classification Criteria as predictors of radiographic damage in early rheumatoid arthritis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.157

Prediction of erosion progression using ultrasound in established rheumatoid arthritis: a 2-year follow-up study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.157

Destructive arthritis, rheumatoid factor, and HLA-DR4. Susceptibility versus severity, a case-control study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.157

Gene-gene and gene-environment interactions involving HLA-DRB1, PTPN22, and smoking in two subsets of rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.157

Interaction between smoking, the shared epitope, and anti-cyclic citrullinated peptide: a mixed picture in three large North American rheumatoid arthritis cohorts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.157

The functional variant of the inhibitory Fcγ receptor IIb (CD32B) is associated with the rate of radiologic joint damage and dendritic cell function in rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.157

Associations between the PTPN22 1858C->T polymorphism and radiographic joint destruction in patients with rheumatoid arthritis: results from a 10-year longitudinal study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.157

Association of the IL4R single-nucleotide polymorphism I50V with rapidly erosive rheumatoid arthritis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.157

Prediction models for rheumatoid arthritis during diagnostic investigation: evaluation of combinations of rheumatoid factor, anti-citrullinated protein/peptide antibodies and the human leucocyte antigen-shared epitope

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.157

Influence of prognostic features on the final outcome in rheumatoid arthritis: a review of the literature

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.157

Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.157

Clinical and radiological efficacy of initial vs delayed treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.157

Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.157

The Molecular Basis of Susceptibility to Rheumatoid Arthritis

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19636334

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

What is the natural history of rheumatoid arthritis?

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19636334

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Prediction of mortality in rheumatoid arthritis based on disease activity markers

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19636334

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRRHEUM.2009.157

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19636334%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

1 reference